![David Yeomans](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Stanley Abel | M | - |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 10 Jahre |
John Mulcahy | M | - |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 Jahre |
George Miljanich | M | - |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 Jahre |
Justin Du Bois | M | - |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 Jahre |
Bruce C. Conway | M | 72 |
Trigemina, Inc.
![]() Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | - |
Mark R. Benham | M | 72 |
Trigemina, Inc.
![]() Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | - |
Scott Braunstein | M | 60 |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 6 Jahre |
Mike R. Shute | M | - |
Trigemina, Inc.
![]() Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | - |
Rick Orr | M | - |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 10 Jahre |
Will Price | M | - |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 9 Jahre |
Alexander Seelenberger Farba | M | 45 |
Trigemina, Inc.
![]() Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | 12 Jahre |
Sandip Biswal | M | - |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Lowell E. Sears | M | 73 |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | - |
Joseph Zakrzewski | M | 60 |
SiteOne Therapeutics, Inc.
![]() SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 6 Jahre |
Rolf K. Hoffmann | M | 64 |
Trigemina, Inc.
![]() Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | - |
Shashidhar H. Kori | M | - |
Trigemina, Inc.
![]() Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | - |
Tom D. McCarthy | M | - |
Trigemina, Inc.
![]() Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 17 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David Yeomans
- Persönliches Netzwerk